Cargando…

SARS-CoV-2 transmissions in students and teachers: seroprevalence follow-up study in a German secondary school in November and December 2020

OBJECTIVE: To quantify the number of undetected SARS-CoV-2 infections in educational settings. DESIGN: Serial SARS-CoV-2 seroprevalence study before and during the second wave of the COVID-19 pandemic. SETTING: Secondary school in Dresden, Germany. PARTICIPANTS: Grade 8–12 students and their teacher...

Descripción completa

Detalles Bibliográficos
Autores principales: Armann, Jakob Peter, Kirsten, Carolin, Galow, Lukas, Kahre, Elisabeth, Haag, Luise, Dalpke, Alexander, Lück, Christian, Berner, Reinhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992381/
https://www.ncbi.nlm.nih.gov/pubmed/34192197
http://dx.doi.org/10.1136/bmjpo-2021-001036
Descripción
Sumario:OBJECTIVE: To quantify the number of undetected SARS-CoV-2 infections in educational settings. DESIGN: Serial SARS-CoV-2 seroprevalence study before and during the second wave of the COVID-19 pandemic. SETTING: Secondary school in Dresden, Germany. PARTICIPANTS: Grade 8–12 students and their teachers were invited to participate in serial blood sampling and SARS-CoV-2 IgG antibody assessment. MAIN OUTCOME MEASURE: Seroprevalence of SARS-CoV-2 antibodies in study population. RESULTS: 247 students and 55 teachers participated in the initial study visit and 197 students and 40 teachers completed follow-up. Seroprevalence increased from 1.7% (0.3–3.3) to 6.8% (3.8–10.1) during the study period mirroring the increase of officially reported SARS-CoV-2 infections during this time. The ratio of undetected to detected SARS-CoV-2 infections ranged from 0.25 to 0.33. CONCLUSIONS: We could not find evidence of relevant silent, asymptomatic spread of SARS-CoV-2 in schools neither in a low prevalence setting nor during the second wave of the pandemic, making it unlikely that educational settings play a crucial role in driving the SARS-CoV-2 pandemic. TRIAL REGISTRATION NUMBER: DRKS00022455.